Views & Analysis

R&D

IPF: Could we reverse the progression?

Idiopathic Pulmonary Fibrosis (IPF) is a frightening, incurable disease where the lungs become increasingly damaged by scar tissue, resulting in breathing getting progressively more difficu

R&D

Reducing the stigma attached to psychedelics

It’s no secret that 2023 has been a year for a shift in thinking when it comes to psychedelics, in particular as pertains to their use for hard-to-treat or treatment resistant mental health

R&D

How clinical research is zeroing in on fatty liver disease

Americans’ livers are becoming increasingly unhealthy.

R&D

Cultivating quality excellence in the clinical trials landsc...

Quality is subjective, with different individuals associating it with various things.

R&D

Implications of regulatory and FDA guidance on diversity, eq...

It is well established that focusing on diversity in clinical trials is essential for developing therapies that are safe and effective for different patient populations.

R&D